ClinicalTrials.gg
Not yet recruitingNCT07108101Updated Oct 7, 2026

Interactions Between Placebo Effects and Mindful Awareness State

An interventional study of tDCS stimulation (sham) and tDCS stimulation (real) in Placebo Effect, Mindfulness and Pain, sponsored by Trustees of Dartmouth College. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Trustees of Dartmouth College · Not applicable, Interventional, and Basic science

How we know

Updated Oct 7, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 2,886 studies in Pain with a site in United States — 315 open to participants now, 393 under way, 24 of them phase 3. Pain · United States.

Planned enrollment
788th of 2,564
120 · median 66
Started
2027
with 14 others
No phase
1,244 of 2,886
183 open now
Primary completion
2029-06
later than 354 of 392 live
Registered
2,729th of 2,886
by date

Among the 2,886 studies in Pain with a site in United States, this one is the 788th largest by planned enrollment of the 2,564 interventional ones that give a count, is one of 15 that started in 2027, is one of 1,244 with no phase, reaches primary completion later than 354 of the 392 other live ones, and was the 2,729th registered.

Pain

10,076 studies on the registry are indexed under Pain; 1,648 are open to participants now.

Browse Pain studies →

Open to participants now

315 of the 2,886 studies in Pain with a site in United States are open now. Recruiting first, the newest first:

310 more — sign in →

All 315 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 930 Pain studies recruiting now, 384 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 220 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,886 studies in Pain with a site in United States, or all of them as a file.
02

Study summary

In this experiment,the investigators study the effects of interpersonally induced placebo effects and a mindful awareness induction on negative affect. Specifically, it will be examining the effects of interpersonally induced placebo effects (sham tDCS vs. control) and a mindful awareness induction (mindful state vs. control), as well as their interaction. Each group will undergo fMRI scanning and physiological recording will performing the Multimodal Negative Affect Task (MNAT).

Read the detailed description

This study aims to investigate the effects of interpersonally induced placebo effects and a mindful awareness induction on negative affect. The study will involve 120 participants recruited from the Dartmouth College community, aged between 18 and 55, with an equal distribution of 60 males and 60 females. Participants will be assigned to the role of "patient" and will undergo fMRI scanning and physiological recording while performing the Multimodal Negative Affect Task (MNAT).

The study design follows a 2 x 2 factorial design, examining the effects of interpersonally induced placebo effects (sham tDCS vs. control) and a mindful awareness induction (mindful state vs. control), as well as their interaction. A follow-up transfer assessment (1 week follow-up, session 2) will be conducted to examine the effects of the mindful state on verum motor tDCS stimulation. The participants will be randomly assigned to either the Mindfulness group or the No-mindfulness group, with 60 participants in each group and two sessions for each participant.

In session 1, participants in the Mindfulness group will undergo a Mindful State Induction procedure aimed at promoting safety, relaxation, and receptivity. This induction procedure consists of two stages. In the first stage, participants will receive education about the brain's connection to and regulation of the body, emphasizing the endogenous brain regulatory capacities. The second stage involves a hypnotic induction of a relaxed state of receptivity using the Stanford Hypnotic Induction Profile (HIP) test of hypnotizability. This stage includes reclining the participant, suggesting that they are always in control, and making somatic suggestions to deepen the receptive state. A guided body scan, derived from mindfulness meditation, will further deepen the induced receptive state.

In contrast, participants in the No-mindfulness group will go through comparable stages but with different instructions. In the first stage, they will receive education about pain and affect as protective processes of the body. In the second stage, they will be seated in an upright, alert posture and receive suggestions to focus on the task and suppress attention to the body.

During the transfer test, conducted in a second fMRI session one week later, we will assess transfer to verum, open-label motor-cortex tDCS in an off-on-off design (both groups), with no explicit mindful state induction. No MRI data will be acquired during tDCS to avoid MR artifacts. We will also assess spontaneous use of strategies, including self-regulation and spontaneous adoption of states of mindful acceptance, and test whether these differ across groups.

The analysis will involve assessing self-report measures, fMRI signatures, and autonomic reactivity to cues and task stimuli, similar to Experiment 1. The analysis will also explore the mediating role of interpersonal response (IPIX scores) and participants' initial responses to placebo.

The researchers plan to control for sex, age, and experimenter effects in all analyses and will test for potential biological sex differences, disaggregating the data if necessary. MRI data will not be acquired during tDCS to avoid artifacts, and the study is not designed to directly compare placebo tDCS with verum tDCS. However, it aims to investigate interpersonal and suggestion-related contributions to open-label treatment responses, providing a foundation for future studies on tDCS and its interactions with placebo effects.

03

Conditions studied

  • Placebo Effect
  • Mindfulness
  • Pain
  • Transcranial Direct Current Stimulation (tDCS)

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

  • No self-reported current or history of depression, bipolar disorder, or other psychiatric diagnosis
  • No self-reported current seizure disorder (i.e., seizure within past 10 years), or history of stroke or other major neurological diagnosis that can cause cognitive impairment
  • No self-reported current chronic pain, or acute pain within three months of the study period
  • No current migraine disorder (i.e., 15 headache days or more in 1 month)
  • No use of central nervous system-effective medication or other medication for neurological/psychiatric treatment
  • No self-reported substance abuse within the last six months
  • No to MRI or tDCS (e.g., pregnancy, claustrophobia, pacemakers, ear/cochlear implants, shrapnel injuries, clips, or other ferromagnetic/electrical objects/devices, diagnosed brain abnormality such as tumor, or skin lesions on the scalp.)
  • No contraindications for induced pain (e.g., no heart disease, high blood pressure, heart surgery, heart problems of any kind, severe asthma, respiratory problems of any kind, fibromyalgia, Raynaud's Syndrome or Disease, chronic pain, diabetes)
  • Participants must be capable of performing experimental tasks (e.g., are able to read), are fluent or native speakers of English
  • Participants must be able to tolerate the maximum level of thermal pain stimuli (for thermal stimuli)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    mindfulness (session 1)+ real tdcs, sham tdcs (session 2)

    Assigned to the mindfulness group in session 1. Will experience real tdcs, followed by sham tdcs for session 2.

    Behavioral: tDCS stimulation (sham) · Behavioral: tDCS stimulation (real) · Behavioral: Mindful state induction

  • Experimental
    mindfulness (session 1) + sham tcds, real tdcs (session 2)

    Assigned to the mindfulness group in session 1. Will experience sham tdcs, followed by real tdcs for session 2.

    Behavioral: tDCS stimulation (sham) · Behavioral: tDCS stimulation (real) · Behavioral: Mindful state induction

  • Experimental
    no mindfulness (session 1) + real tdcs, sham tcds (session 2)

    Assigned to the no-mindfulness control group in session 1. Will experience real tdcs, followed by sham tdcs for session 2.

    Behavioral: tDCS stimulation (sham) · Behavioral: tDCS stimulation (real) · Behavioral: No minfulness induction

  • Experimental
    no mindfulness (session 1) + sham tdcs, real tdcs (session 2)

    Assigned to the no-mindfulness control group in session 1. Will experience sham tdcs, followed by real tdcs for session 2.

    Behavioral: tDCS stimulation (sham) · Behavioral: tDCS stimulation (real) · Behavioral: No minfulness induction

Interventions

  • BehavioraltDCS stimulation (sham)

    Participants will receive sham tDCS stimulation in a 20 minute long task. Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Sham tDCS will target the motor cortex at 2mA for 15 sec at the beginning of the session, and then the stimulator will turn off. The participant will then sit for the remaining time of the session with the electrode cap on their heads but turned off and not delivering stimulation. All participants will receive sham tDCS stimulation (n=120).

  • BehavioraltDCS stimulation (real)

    In their second session, participants will receive real tDCS stimulation in a 20 minute long task. Targets will be fitted with the tDCS stimulation electrode cap and instructed that they will receive 20 minutes of tDCS stimulation for the task. Real tDCS stimulation will target the motor cortex at 2mA for 20 minutes (full duration of task). All participants will receive real tDCS stimulation (n=120).

  • BehavioralMindful state induction

    Experimenters trained in high-competence and high-warmth will train Group 1 participants on mindful state induction (n=60). Participants will undergo two stages for this training: 1) pain education to increase beliefs in endogenous brain regulatory capacities; and 2) the Stanford Hypnotic Induction Profile (HIP) test of hypnotizability and hypnotic induction of a relaxed state receptive to suggestion. In Stage 1, participants will receive education that pain and affect are processes designed to protect the body from danger, which are transmitted rapidly and automatically to the brain. In Stage 2, participants are (a) seated in an upright, alert posture; and (b) receive suggestions that the ability to attend to and discriminate affective perceptions is achievable and that suppressing attention to the body and focusing on the task will allow them to perform optimally under pressure. Mindful state induction will only be explicitly instructed during session 1 for Group 1 participants.

  • BehavioralNo minfulness induction

    Participants in the No-mindfulness group will go through comparable stages but with different instructions. In the first stage, they will receive education about pain and affect as protective processes of the body. In the second stage, they will be seated in an upright, alert posture and receive suggestions to focus on the task and suppress attention to the body.

06

What researchers measure

Primary outcomes

  1. Pain Ratings

    Participants report subjective pain experience after each trial on a well-validated Generalized Linear Magnitude scale (GLMS) with anchors of "No pain" and "Most intense pain imaginable". Raw units are on a 0-180 scale.

    Time frame: 3-10 sec post-stimulus throughout testing sessions, with all sessions complete within 1 month

  2. Subjective fear ratings

    Participants report subjective fear experience after each trial on a well-validated Generalized Linear Magnitude scale (GLMS) with anchors of "No fear" and "Most intense fear imaginable"

    Time frame: 3-10 sec post-stimulus throughout testing sessions, with all sessions complete within 1 month

  3. Cognitive effort ratings

    Participants report cognitive effort experience after each trial on a well-validated Generalized Linear Magnitude scale (GLMS) with anchors of "No effort" and "Most effort imaginable"

    Time frame: 3-10 sec post-stimulus throughout testing sessions, with all sessions complete within 1 month

Secondary outcomes

  1. Electrodermal autonomic responses to painful heat, fear-related images and cognitive effort.

    Skin conductance (EDA) is recorded continuously throughout test sessions and per-stimulus amplitude of canonical stimulus-locked EDA responses is reported in microsiemens (uS). Higher values indicate a higher EDA response.

    Time frame: Peri-stimulus throughout testing sessions, with all sessions complete within 1 month

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2027; primary completion for Jun 2029, 24 months later.

Of 3,749 non-industry interventional studies with no phase under Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 23. This study's planned 24 months is above that.

Counting every sponsor, half of 3,848 studies reached it within 10 months; a quarter within 4 and three quarters within 23.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 7, 2026: start Jun 2026 → Jun 2027, primary completion Jun 2028 → Jun 2029 and completion Nov 2028 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2025
First posted
Aug 6, 2025
StartEst.
Jun 1, 2027was Jun 2026
Primary completionEst.
Jun 1, 2029was Jun 2028
CompletionEst.
Nov 30, 2029was Nov 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jun 1, 2026→Jun 1, 2027
Oct 7, 2026
Primary completion
Jun 1, 2028→Jun 1, 2029
Oct 7, 2026
Study completion
Nov 30, 2028→Nov 30, 2029
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Start date Jun 1, 2026→Jun 1, 2027
    Primary completion Jun 1, 2028→Jun 1, 2029
    Study completion Nov 30, 2028→Nov 30, 2029
    + 3 other changes: verification date, oversight details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07108101
Lead sponsor
Trustees of Dartmouth College
Responsible party
Tor Wager (Diana L. Taylor Distinguished Professor, Trustees of Dartmouth College) — Principal investigator
First posted
Aug 6, 2025
Start date
Jun 1, 2027 (estimated)
Primary completion
Jun 1, 2029 (estimated)
Completion
Nov 30, 2029 (estimated)
Last update
Oct 7, 2026

Study contacts

Tor Wager, Ph.D.
Contact
tor.d.wager@dartmouth.edu
6036462196
Tor Wager, Ph.D.
principal investigator · Dartmouth College

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion